VVUS - Risky But Moving Up And Reclaiming Losses

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

SHORT INTEREST
541.95K 07/31/19

P/E Current
-1.14

P/E Ratio (with extraordinary items)
-1.53

Average Recommendation: HOLD

Average Target Price: 10.00